|
[1]TE HS,JENSEN DM.Epidemiology of hepatitis B and C viruses:a global overview[J].Clin Liver Dis,2010,14(1):1-21,vii.
|
|
[2]NIE AH.Recent advances in HCV NS5B RNA-dependent RNA polymerase inhibitors[J].J Int Pharm Res,2012,39(2):89-103.(in Chinese)聂爱华.丙型肝炎病毒NSSB RNA聚合酶抑制剂研究进展[J].国际药学研究杂志,2012,39(2):89-103.
|
|
[3]GANE EJ,STEDMAN CA,HYLAND RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C[J].N Engl JMed,2013,368(1):34-44.
|
|
[4] LAWITZ E,MANGIA A,WYLES D,et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med,2013,368(20):1878-1887.
|
|
[5]JACOBSON IM,GORDON SC,KOWDLEY KV,et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med,2013,368(7):1867-1877.
|
|
[6]ZEUZEM S,DUSHEIKO GM,SALUPERE R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med,2014,370(21):1993-2001.
|
|
[7]AFDHAL N,ZEUZEM S,KWO P,et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med,2014,370(20):1889-1898.
|
|
[8] AFDHAL N,REDDY KR,NELSON DR,et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J].N Engl J Med,2014,370(16):1483-1493.
|
|
[9]KOWDLEY KV,GORDON SC,REDDY KR,et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med,2014,370(20):1879-1888.
|
|
[10]LAWITZ E,SULKOWSKI MS,GHALIB R,et al.Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOSrandomised study[J].Lancet,2014,384(9956):1756-1765.
|
|
[11]KWO P,GITLIN N,NAHASS R,et al.LP14:a phase 3,randomised,open-label study to evaluate the efficacy and safety of 8 and12 weeks of simeprevir(SMV)plus sofosbuvir(SOF)in treatment-nave and-experienced patients with chronic HCV genotype 1infection without cirrhosis:optimist-1[J].J Hepatol,2015,62(2):s270.
|
|
[12]FORMAN LM,LEWIS JD,BERLIN JA,et al.The association between hepatitis C infection and survival after orthotopic liver transplantation[J].Gastroenterology,2002,122(4):889-896.
|
|
[13]GANE EJ.The natural history of recurrent hepatitis C and what influences this[J].Liver Transpl,2008,14(2):s36-s44.
|
|
[14]CURRY MP,FORNS X,CHUNG RT,et al.Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation:an open-label study[J].Gastroenterology,2015,48(1):100-107.
|
|
[15]SAMUEL D,CHARLTON M,GANE E,et al.P1232 sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation:results of a prospective,multicenter study[J].J Hepatol,2014,60(1):s499.
|
|
[16]FORNS X,PRIETO M,CHARLTON M,et al.O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation[J].J Hepatol,2014,60(1):s26.
|
|
[17]SULKOWSKI MS,NAGGIE S,LALEZARI J,et al.Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection[J].JA-MA,2014,312(18):353-361.
|
DownLoad: